Elastin Aggregates as a Protective Aggresome-like Response to Vascular Proteotoxic Stress

Hypothesis

We propose that insoluble tropoelastin aggregates observed in aging arteries are not pathological debris but a spatially organized, energy‑dependent sequestration mechanism akin to the cytoplasmic IPOD/JUNQ system. When vascular smooth muscle cells (VSMCs) experience chronic oxidative stress and elastin‑crosslinking defects, they actively redirect misfolded tropoelastin into a peripheral aggrematrix that reduces soluble oligomer toxicity and stores the protein for later clearance via autophagy‑lysosomal pathways.

Mechanistic Model

1. Stress sensing – Elevated ROS and altered NADPH oxidase activity in VSMCs trigger phosphorylation of the small HspB family (e.g., HspB1) and up‑regulation of the co‑chaperone BAG3.
2. Chaperone‑mediated targeting – HspB1 binds nascent misfolded tropoelastin oligomers, lowering their surface‑to‑volume ratio and promoting interaction with HDAC6‑dynein motors.
3. Active transport – HDAC6‑dependent dynein drives oligomers along microtubules to a perinuclear elastin‑rich compartment we term the vascular IPOD (vIPOD), analogous to the yeast IPOD.
4. Aggresome formation – Within the vIPOD, HspB1‑αB‑crystallin complexes nucleate higher‑order β‑sheet‑rich fibrils that are physically cross‑linked by lysyl oxidase‑like (LOXL) enzymes, generating a stable elastin aggrematrix.
5. Clearance gate – The aggrematrix is sequestered away from the luminal surface, limiting elastin‑derived calcification nuclei. Periodic activation of TFEB drives lysosomal docking and autophagic removal of the vIPOD content; failure of this step leads to progressive arterial stiffening.

Testable Predictions

• Perturbation of HspB1 or HDAC6 in cultured human aortic VSMCs will increase soluble tropoelastin oligomers (detected by conformation‑specific ELISA) and exacerbate calcific nodule formation under β‑glycerophosphate challenge, whereas over‑expression will shift tropoelastin into a detergent‑insoluble fraction co‑localizing with HDAC6 and LC3.
• In vivo, mice with VSMC‑specific knockout of HspB1 will develop accelerated elastin fragmentation and pulse‑wave velocity rise compared with littermate controls, while aggrematrix‑stabilizing peptides (e.g., HspB1‑mimetic) will rescue stiffness without altering total elastin deposition.
• Pharmacological blockade of autophagic flux (chloroquine) after inducing the vIPOD will cause accumulation of the aggrematrix and secondary increase in arterial calcification, confirming that the aggregate is a transient protective store rather than a dead‑end product.
• Spatial proteomics of human atherosclerotic plaques will reveal enrichment of ubiquitinated tropoelastin, HspB1, HDAC6, and LC3 in the medial layer, mirroring the IPOD/JUNQ segregation seen in neurodegenerative models.

Falsifiable Outcomes

If inhibiting HspB1 or HDAC6 reduces soluble tropoelastin oligomers and improves arterial mechanics, or if aggrematrix formation does not correlate with decreased calcification, the hypothesis that elastin aggregation serves a protective, organized quality‑control role would be refuted.